Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07217470 · ClinicalTrials.gov registry record

Fluid Status of ESRD Patients Undergoing Dialysis

A clinical trial, sponsored by HemoCept.

Completed
Registry status
26
Enrollment target

NCT07217470: Completed study, sponsored by HemoCept.

NCT07217470 is a clinical trial that has completed, run by HemoCept. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07217470 has completed, sponsored by HemoCept.

COMPLETED
Registry status
26 participants
Enrollment target

Study Summary

The pilot clinical study will assess the correlation between fluid removal during dialysis and HemoCept device data.

Primary Outcome

The primary analysis will be conducted using HemoCept device readings taken before dialysis and at the end of dialysis, just prior to return of blood and fluid from the machine. The device data will then be assessed for its comparison to dry weight changes.

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2025-08-18
Est. Completion 2025-11-20
HemoCept

4 total trials

What the finished NCT07217470 record still lists

NCT07217470 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT07217470 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07217470 about?

NCT07217470 is a clinical study titled "Fluid Status of ESRD Patients Undergoing Dialysis". The pilot clinical study will assess the correlation between fluid removal during dialysis and HemoCept device data.

What is the current status of trial NCT07217470?

This trial is currently completed. The enrollment target is 26 participants. The study started on 2025-08-18. Estimated completion is 2025-11-20.

Who is sponsoring clinical trial NCT07217470?

This trial is sponsored by HemoCept, which has 4 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07217470, the US trial registry maintained by the National Library of Medicine. NCT07217470 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.